CA2777546C - Treating neurotoxicity associated with combinations of 5-fu or its prodrugs and dpd inhibitors - Google Patents

Treating neurotoxicity associated with combinations of 5-fu or its prodrugs and dpd inhibitors Download PDF

Info

Publication number
CA2777546C
CA2777546C CA2777546A CA2777546A CA2777546C CA 2777546 C CA2777546 C CA 2777546C CA 2777546 A CA2777546 A CA 2777546A CA 2777546 A CA2777546 A CA 2777546A CA 2777546 C CA2777546 C CA 2777546C
Authority
CA
Canada
Prior art keywords
eniluracil
prodrug
fluoro
fluorouracil
fluorouridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2777546A
Other languages
English (en)
French (fr)
Other versions
CA2777546A1 (en
Inventor
Thomas Spector
Original Assignee
Elion Oncology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elion Oncology LLC filed Critical Elion Oncology LLC
Publication of CA2777546A1 publication Critical patent/CA2777546A1/en
Application granted granted Critical
Publication of CA2777546C publication Critical patent/CA2777546C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2777546A 2009-10-14 2010-10-14 Treating neurotoxicity associated with combinations of 5-fu or its prodrugs and dpd inhibitors Active CA2777546C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25144909P 2009-10-14 2009-10-14
US61/251,449 2009-10-14
PCT/US2010/052734 WO2011047195A1 (en) 2009-10-14 2010-10-14 Treating neurotoxicity associated with combinations of 5 - fu or its prodrugs and dpd inhibitors

Publications (2)

Publication Number Publication Date
CA2777546A1 CA2777546A1 (en) 2011-04-21
CA2777546C true CA2777546C (en) 2019-11-05

Family

ID=43466528

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2777546A Active CA2777546C (en) 2009-10-14 2010-10-14 Treating neurotoxicity associated with combinations of 5-fu or its prodrugs and dpd inhibitors

Country Status (14)

Country Link
US (1) US8658618B2 (enExample)
EP (1) EP2488182B1 (enExample)
JP (2) JP2013508293A (enExample)
KR (1) KR20120127709A (enExample)
CN (1) CN102811721A (enExample)
AU (1) AU2010306698B2 (enExample)
BR (1) BR112012008951A2 (enExample)
CA (1) CA2777546C (enExample)
CO (1) CO6541596A2 (enExample)
EA (1) EA201270551A1 (enExample)
ES (1) ES2644237T3 (enExample)
IL (1) IL219179A0 (enExample)
MX (1) MX2012004383A (enExample)
WO (1) WO2011047195A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024123736A1 (en) * 2022-12-06 2024-06-13 Elion Oncology, Inc. Combined use of eniluracil and capecitabine for treating cancer

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089004A1 (en) * 2012-12-04 2014-06-12 Adherex Technologies, Inc. Methods for treating 5-fluorouracil prodrug non-responsive cancer patients
CN106692173A (zh) * 2015-11-18 2017-05-24 北京诺普德医药科技有限公司 一种抗肿瘤复方组合物及其应用
AR133242A1 (es) * 2023-07-13 2025-09-10 Processa Pharmaceuticals Inc Métodos de personalización del tratamiento contra el cáncer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5687599A (en) 1979-12-19 1981-07-16 Yamasa Shoyu Co Ltd E 55 22halogenovinyl arabinofuranosyluracil and its preparation
GB8629892D0 (en) 1986-12-15 1987-01-28 Wellcome Found Antiviral compounds
US5157114A (en) 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
ATE161722T1 (de) * 1990-07-19 1998-01-15 Wellcome Found Enzyminaktivatoren
GB9020930D0 (en) * 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
US5476855A (en) 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
CN102441170A (zh) * 2004-12-03 2012-05-09 阿迪赫里克斯技术公司 与5-fu和5-fu前药组合施用dpd抑制剂的方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024123736A1 (en) * 2022-12-06 2024-06-13 Elion Oncology, Inc. Combined use of eniluracil and capecitabine for treating cancer

Also Published As

Publication number Publication date
IL219179A0 (en) 2012-06-28
EA201270551A1 (ru) 2012-12-28
BR112012008951A2 (pt) 2019-09-24
MX2012004383A (es) 2012-08-23
EP2488182A1 (en) 2012-08-22
EP2488182B1 (en) 2017-07-19
CN102811721A (zh) 2012-12-05
US8658618B2 (en) 2014-02-25
KR20120127709A (ko) 2012-11-23
AU2010306698A1 (en) 2012-05-17
AU2010306698B2 (en) 2016-05-26
JP2013508293A (ja) 2013-03-07
CA2777546A1 (en) 2011-04-21
ES2644237T3 (es) 2017-11-28
JP2016014051A (ja) 2016-01-28
US20110130359A1 (en) 2011-06-02
WO2011047195A1 (en) 2011-04-21
CO6541596A2 (es) 2012-10-16

Similar Documents

Publication Publication Date Title
US20130184232A1 (en) Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
KR101468216B1 (ko) α,α,α-트리플루오로티미딘과 티미딘포스포릴라아제저해제를 배합한 항암제
Hong et al. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS‐102 in patients with solid tumors
USRE46284E1 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
CN114727996A (zh) 用于治疗白血病或骨髓增生异常综合征的与维奈托克、吉瑞替尼、米哚妥林或其他化合物组合的阿扎胞苷
US8658618B2 (en) Methods for preventing or reducing neurotoxicity associated with administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
KR20240108406A (ko) 2'-데옥시시티딘 유사체를 포함하는 조성물 및 겸상 적혈구 질환, 지중해빈혈, 및 암의 치료를 위한 그의 용도
JP2007508299A (ja) 全身性抗癌治療の間の器官保護のための方法、組成物、およびキット
AU2012200856B2 (en) Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
JP2013508293A5 (enExample)
US20080255168A1 (en) Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
WO2014089004A1 (en) Methods for treating 5-fluorouracil prodrug non-responsive cancer patients
HK1110531A (en) Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
EA045934B1 (ru) Комбинированные твердые пероральные лекарственные формы децитабина и цедазуридина
US20080153858A1 (en) Antitumorigenic drug combination

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151014

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241004

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241004

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251010

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251010